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Perioperative epidural analgesia for major abdominal
surgery for cancer and recurrence-free survival: randomised
trial
Paul S Myles, professor,1 director,2 Philip Peyton, consultant,3 Brendan Silbert, consultant,4 Jennifer Hunt,
research coordinator,1 John R A Rigg, retired consultant,5 Daniel I Sessler, professor and chair6 for the ANZCA
Trials Group Investigators
ABSTRACT
Objective To compare long term recurrence of cancer and
survival of patients having major abdominal surgery for
cancer.
Design Long term follow-up of prospective randomised
controlled clinical trial in which patients were randomly
assigned to receive general anaesthesia with or without
epidural block for at least three postoperative days.
Setting 23 hospitals in Australia, New Zealand, and Asia.
Participants 503 adult patients who had potentially
curative surgery for cancer.
Main outcome measure Cancer-free survival (analysis
was by intention to treat).
Results Long term follow-up data were available for 94%
(n=446) of eligible participants. The median time to
recurrence of cancer or death was 2.8 (95% confidence
interval 0.7 to 8.7) years in the control group and 2.6 (0.7
to 8.7) years in the epidural group (P=0.61). Recurrence-
free survival was similar in both epidural and control
groups (hazard ratio 0.95, 95% confidence interval 0.76
to 1.17; P=0.61).
ConclusionUse of epidural block in abdominal surgery for
cancer is not associated with improved cancer-free
survival.
Trial registration Australian New Zealand Clinical Trials
Registry ACTRN12607000637448
INTRODUCTION
Even with the best technique, surgery for cancer is
usually associated with release of cancer cells into the
lymphatic system and bloodstream, and a large frac-
tion of patients already havemicrometastases and scat-
tered cancer cells at the time of surgery.1 Whether
residual postoperative cancer results in clinical meta-
stases depends largely on the balance between anti-
metastatic immune activity and the tumour’s ability
to seed, proliferate, and attract new blood vessels.2 In
practice, the immune system and other host defences
often fail to neutralise minimal residual disease; conse-
quently, local recurrence and metastatic disease
remain common after surgery.
At least three perioperative factors threaten com-
plete surgical eradication of cancer. The first is surgery
itself, which releases cancer cells into the circulation,1
depresses cell mediated immunity including functions
of cytotoxic T cells and natural killer cells,3 reduces
circulating concentrations of tumour related anti-
angiogenic factors (such as angiostatin and endo
statin),4 increases concentrations of pro-angiogenic fac-
tors such as vascular endothelial growth factor,5 and
releases growth factors that promote local and distant
growth ofmalignant tissue.2 The second factor is anaes-
thesia itself, which impairs many immune functions,
including functions of neutrophils, macrophages, den-
dritic cells, T cells, and natural killer cells.6 The third
factor is opioids, which are given to control surgical
pain. Opioids inhibit both cellular and humoral
immune function in humans.6 Furthermore, morphine
is pro-angiogenic and promotes growth of breast
tumours in rodents.7 Consequently, non-opioid
analgesia helps to preserve the functionof natural killer
cells in animals and humans and reduces metastatic
spread of cancer in rodents.8
Regional anaesthesia (intraoperative block of noci-
ception) and analgesia (postoperative pain relief)
attenuate or prevent each of these adverse effects. For
example, regional anaesthesia largely prevents the
neuroendocrine stress response to surgery by blocking
afferent neural transmission from reaching the central
nervous system and activating the stress response and
by blocking descending efferent activation of the sym-
pathetic nervous system,9 so little if any opioid analge-
sia is needed. Regional analgesia also reduces release
of endogenous opioids.10 Consequently, little opioid
induced immune impairment occurs.9 As might be
expected, surgical stress is attenuated better by regio-
nal than by general anaesthesia. Consequently, natural
killer cell function is better preserved and metastatic
load to the lungs is reduced in a rat model of breast
cancer metastasis.3
Available data thus suggest that regional block with
local anaesthetic helps to preserve effective defences
against progression of tumour by attenuating the
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surgical stress response, by reducing or eliminating the
need for volatile anaesthetics, and by sparing post-
operative opioids. Animal studies are consistent with
this theory, showing that regional block can reduce the
metastatic burden in animals inoculated with breast
adenocarcinoma cells.3 11 Only small observational
studies are available in humans; two reported benefi-
cial effects with regional anaesthesia in breast cancer
and prostate cancer,12 13 whereas three others did not
in colon cancer, prostate cancer, and cervical
cancer14-16; another reported equivocal results in pros-
tate cancer.17
We previously did a multicentre randomised trial
comparing regional block in patients having major
abdominal surgery,manyofwhomwere having poten-
tially curative resection of cancer, mostly colon
cancer.18 Patients in this MASTER trial had surgery
9-15 years ago, providing a unique opportunity to
assess their cancer status and long term survival. Our
aim was to identify whether epidural block reduces
recurrence of cancer and improves survival. Specifi-
cally, we tested the hypothesis that epidural block for
patients with comorbidity having major abdominal
surgery and apparently complete resection of cancer
reduces the risk of recurrence of cancer and death.
METHODS
Study design and participants
A detailed description of the design and 30 day out-
comes of the MASTER trial has been previously
published.18-20 MASTER was a multicentre rando-
mised clinical trial designed to test the hypothesis that
combined epidural and general anaesthesia reduces
the frequency of a composite end point of mortality
and major postoperative complications compared
with general anaesthesia and opioid analgesia.19 It
enrolled 915 patients havingmajor abdominal surgery
between July 1995 and May 2001. Patients were ran-
domly assigned to receive intraoperative epidural
anaesthesia and postoperative epidural analgesia (epi-
dural group) or postoperative intravenous opioid
based analgesia (no epidural group); all patients
received general anaesthesia during surgery.
The protocol provided guidelines for premedica-
tion, intraoperative monitoring, site of the epidural
(to be selected by the consultant anaesthetist to match
the planned incision), use of intraoperative and post-
operative epidural local anaesthetics to provide epi-
dural block during and after surgery, induction and
maintenance of general anaesthesia, replacement of
blood and fluids, optimisation of core temperature
and respiratory and cardiac function, criteria for tra-
cheal extubation, and immediate postoperative medi-
cal management. With the exception of some pelvic
operations, all epidural catheters were inserted in the
thoracic region. Postoperative analgesia in the non-
epidural group was mostly achieved with patient con-
trolled, opioid based analgesia. In the epidural group,
postoperative analgesia was managed with continuous
infusions of bupivacaineor ropivacaine, supplemented
with fentanyl or pethidine. Epidural analgesiawas typi-
cally continued for three days after surgery.
For the clinical assessment of epidural block, we
recordedminimum andmaximum heart rates and sys-
tolic blood pressures during surgery in all patients as
indicators of the clinical efficacy of intraoperative epi-
dural block. After surgery, we measured intensity of
pain at rest and after coughing in all patients by using
a 10 cm visual analogue scale twice daily for the first
three postoperative days as an indicator of effective
pain control. Morphine remains the most widely used
intraoperative and early postoperative opioid analge-
sic. Opioid usage was not recorded in the original
MASTER trial database. We were none the less able
to determine morphine use in the initial 72 postopera-
tive hours from a single high recruiting site. We con-
verted other opioids to morphine sulphate equivalents
at ratios of 10:1 (pethidine) and 1:100 (fentanyl).
In the original study, among 440 patients rando-
mised to the non-epidural group 19 (4.3%) had epi-
dural analgesia established preoperatively or within
72 hours of surgery. Among 447 patients randomised
to epidural analgesia, 29 (6.5%) did not receive an epi-
dural, but in only 13 of these had it been unsuccessfully
attempted (failure rate 4.6%). Among the remaining
patients, the average duration for which the epidural
remained in situ postoperatively was 74 hours. In this
analysis, we analysed the height of epidural block
achieved in the first three postoperative days and
report maximal height as another indicator of effective
postoperative epidural block. Use of nitrous oxide was
not recorded in the original study, but the usual prac-
tice at that time was to include it in most cases.
An additional inclusion criterion for the follow-up
study was that patients had complete surgical excision
of cancer. Types of surgery included oesophagectomy,
gastrectomy, hepatectomy, pancreatectomy, colect-
omy, nephrectomy, cystectomy, radical hysterectomy,
and open prostatectomy. We excluded patients who
were not having surgery for cancer (for example, aortic
surgery) or in whom excision of the cancer wasmacro-
scopically incomplete, including those with distant
metastasis at the time of surgery.
In this follow-up study, we collected additional data
relating to type and size of cancer and extent of spread
at the time of the original surgery. This required retro-
spective review of the medical records of all patients
relating to the time of their original surgery, including
pathology reports, formal reporting to cancer regis-
tries, operation reports, and discharge summaries.
We used organ specific tumour-nodes-metastases sta-
ging and the American Joint Commission on Cancer
tumour grading system to characterise the extent of
malignancy and spread of cancer.21
Follow-up of patients
Additional ethics approvals enabled us to search exist-
ing databases for evidence of recurrence of cancer,
death, and cause of death. We were sensitive to the
possible distress associated with late follow-up of
patients who had had surgery for cancer many years
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earlier, including to their families, and the patients’
rights to confidentiality of hospital and cancer registry
data.We therefore developed an algorithm that would
minimise direct contact with patients or families and
protect the confidentiality of individual patients’ data.
We sought follow-up data in the following order: the
patient’s medical record from the source hospital, hos-
pital surgery or pathology databases (or both), the
patient’s general practitioner, state based cancer regis-
try or national death index (or both), letter of introduc-
tion followed by telephone contact of the patient, and
letter of introduction followed by telephone contact of
the patient’s next of kin. We used an approved script
for the telephone contactwith the patient or next of kin.
The ethics committee from one centre amended the
protocol to prevent patients being contacted by
researchers, as some patients may not have been
made aware of their original diagnosis of cancer;
another centre permitted patients to be contacted
only through the patient’s general practitioner. All
other centres’ ethics committees approved the follow-
up procedures as outlined in the protocol.
We also searchedmedical records and registrieswith
a patient identification number, date of birth, and date
of surgery. The Australian national death index
records multiple causes of death. These include those
conditions involved in the morbid train of events lead-
ing to death that were classified as the underlying
cause, the immediate cause, or any intervening causes
and those conditions that contributed to death butwere
not related to the disease or condition that caused
death. We classified the cause of death as primarily
due to cancer, cardiovascular disease, sepsis, and
other causes.
Study end points
The primary end point of the study was cancer-free
survival after surgery; the secondary endpoint was sur-
vival (all causemortality).We calculated recurrence of
cancer and survival from the date of surgery until the
event occurred or until last known contact. We cen-
sored patients who were lost to follow-up at the time
of last record. Research staff blinded to exposure status
collected all outcome data.
A preliminary evaluation of the original MASTER
trial database suggested that about 600 patients had
complete surgical excision of a cancer and would be
eligible for inclusion in this follow-up study. Most of
these patients had primary colorectal cancer, for
which five year survival is approximately 50% and
12 year survival is less than 20%. If epidural block
reduced recurrence-free survival by 25%, then 250
patients per group would provide 89% power with a
two sided α of 0.05. For a reduction from 50% to
37.5% (a relative reduction of 25%) in cumulative five
year survival, 247 patients per group (total 494) would
be needed to provide 80% power with a two sided α of
0.05. However, a relative reduction of a third (from
50% to 33%) would require only 131 patients per
group.
Statistical analysis
We based analyses on the intention to treat principle;
we thus included all randomised patients who had
potentially curative surgery for cancer. We con-
structed time to recurrence and, separately, time to
death from any cause for both groups with Kaplan-
Meier survival estimates and compared them by
using the log-rank test. We used a Cox proportional
hazards model to adjust for imbalances of potentially
important covariates, with assessment of the requisite
proportionality assumptions. We planned to include
patients’ sex, age, and type of surgery in our adjusted
analyses and tests of subgroup interaction. Also, in
view of recent publications suggesting a possible effect
modification of age groups under 65 years and 65 years
or over,14 local spread at the time of surgery,22 and sur-
vival pattern after surgery,22 we did additional post hoc
exploratory analyses to investigate such effects.
Because the outcomes of cancer are usually sum-
marised in terms of five year survival and five year
disease-free survival, we also examined these end
points, initially with two by two tables assessed with
the χ2 test and then in a multivariate logistic model
with recurrence of cancer or death from any cause
within five years of surgery as the end point. We
express results as either hazard ratios or risk ratios
with 95% confidence intervals.
Subgroup analyses assessed patients’ sex, age
groups, and each major organ surgery. For these fac-
tors,we tested for interactionbyusing theBreslow-Day
test for homogeneity of odds ratios across strata.23
Because previous studies have suggested a variable
effect of epidural block over shorter (<1.5 years) and
longer time frames after surgery,22 we assessed this
effect in our dataset. We used SPSS for Windows, ver-
sion 18 for analyses.
RESULTS
Of the original 915 eligible patients in the MASTER
trial, 163 had vascular surgery alone and 246 patients
had major abdominal surgery for non-cancer causes;
Patients assessed for eligibility (n=915)
Had surgery for cancer (n=506)
Epidural (n=263)No epidural (n=240)
Analysed (n=230)Analysed (n=216)
Non-cancer surgery (n=409):
  Vascular surgery (n=163)
  Abdominal organ surgery (n=246)
Inoperable (n=12)
Lost to follow-up (n=12)
Inoperable (n=19)
Refused consent (n=1)
Lost to follow-up (n=13)
Unsure of status (n=3)
Fig 1 | Trial profile
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31 had distant metastases at the time of surgery and
thus had incompletely resectable cancer; a further
three patients were unclassified (fig 1). Patients were
followed up fromMarch 2009 toMay 2010.Nopatient
or next of kin refused; one local medical practitioner
refused to attempt to contact a patientwhowas thought
to be alive, not having seen the patient for more than
eight years. Some centres were unable to follow up
patients because medical records had been destroyed
and electronic hospital databases were unavailable; we
were thus unable to determine survival status or date of
death for a further 24 patients. Only four (<1%) of the
patients had incomplete (censored) data within the first
five years after surgery.
Table 1 shows the distribution of perioperative risk
factors in both groups. Baseline characteristics of the
two groups, asmight be expected from the randomised
design, were comparable in each group. Types of can-
cer surgery, and measures of tumour invasiveness and
differentiation, were also similar in the two groups.
Patients assigned to epidural anaesthesia were given
more intravenous fluid and more red cell transfusions,
as might be expected from the sympathetic block asso-
ciatedwith effective epidural anaesthesia (table 2). The
median maximal block height over the first three days
after surgery in the epidural groupwas thoracic derma-
tome T4 (interquartile range T2-T6, range T1-T10).
Four patients received at least one dose of pethidine,
and three were each given a single dose of fentanyl.
Median morphine sulphate equivalent usage over the
first 72 hours after surgery was 0 (interquartile range 0-
31) mg for epidural patients and 107 (44-202) mg for
control patients (P<0.001).
The median time to recurrence of cancer or death
was 2.6 (interquartile range 0.7-8.7) years in the epi-
dural group and 2.8 (0.7-8.7) years in the non-epidural
group (P=0.61). Recurrence-free survival was similar
in both epidural and non-epidural groups (hazard
ratio 0.95, 95% confidence interval 0.76 to 1.17;
P=0.61 (fig 2). Five year recurrence and mortality
rates were comparable (table 3). We found no inter-
action across each of the three pre-defined subgroups
(fig 3, all P>0.10). Recurrence-free survival remained
essentially unchangedwhen restricted to 1.5 years after
surgery (hazard ratio 0.95, 0.75 to 1.36; P=0.95). An
analysis that included all the additional patients who
had distant metastatic disease at the time of surgery
but still had complete resection of the primary cancer
(n=22) showed a similar risk of cancer-free survival
(hazard ratio 0.94, 0.76 to 1.16; P=0.56).
Cox regression identified significant predictors of
early death or recurrence of cancer as patient’s age
(P<0.001), female sex (hazard ratio 0.65, 0.52 to 0.82;
P<0.001), and red cell transfusion (hazard ratio 0.63,
0.47 to 0.84; P=0.002) but not epidural group (hazard
ratio 1.04, 0.84 to 1.30; P=0.72). After adjustment for
age and sex, type of cancer surgery had no significant
effect on cancer-free survival (P=0.31). These estimates
were similar after inclusion of the degree of differentia-
tion of the cancer, tumour-nodes-metastases classifica-
tion, or both at the time of surgery. Causes of death did
Table 1 | Characteristics of patients at entry. Values are
numbers (percentages) unless stated otherwise
Epidural
(n=230)
No epidural
(n=216)
Demographic characteristics
Mean (SD) age (years) 71 (9.5) 70 (11)
Age group (years):
≤50 5 (2) 11 (5)
51-60 26 (11) 30 (14)
61-70 75 (33) 71 (33)
71-80 87 (38) 75 (35)
>80 37 (16) 29 (13)
Male sex 138 (60.0) 114 (53)
Site of surgery
Oesophagogastric 24 (10) 34 (15)
Hepatobiliary/pancreatic 34 (15) 28 (13)
Bowel 128 (56) 108 (50)
Renal 11 (5) 19 (9)
Prostate/bladder 8 (3) 3 (1)
Uterine/ovarian 20 (9) 20 (9)
Other 5 (2) 5 (2)
Characteristics of cancer
Large bowel: (n=58) (n=54)
Duke’s A 12 (21) 12 (22)
Duke’s B 27 (47) 23 (43)
Duke’s C 19 (33) 23 (43)
TNM classification: (n=125) (n=106)
T1 27 (22) 16 (15)
T2 25 (20) 30 (28)
T3 70 (56) 52 (49)
T4 3 (2) 8 (8)
N0 81 (65) 68 (64)
N1 35 (28) 27 (25)
N2 10 (8) 11 (10)
Tumour grade: (n=145) (n=140)
Well to moderately differentiated 16 (11) 17 (12)
Poorly differentiated 102 (70) 89 (64)
Undifferentiated 27 (19) 34 (24)
Pre-existing medical conditions
Morbid obesity 7 (3) 7 (3)
Chronic obstructive lung disease 25 (11) 17 (8)
Previous myocardial infarction 23 (10) 15 (7)
Diabetes 114 (50) 122 (56)
Heart failure 26 (11) 16 (7)
Hepatic failure 23 (10) 19 (9)
Renal failure 5 (2) 10 (5)
Blood tests—mean (SD)
Sodium (mmol/L) 140 (3.6) 139 (4.0)
Potassium (mmol/L) 4.3 (0.5) 4.2 (0.5)
Creatinine (µmol/L) 109 (119) 106 (78)
Urea (mmol/L) 6.6 (4.1) 6.6 (3.7)
Albumin (mmol/L) 36 (5.8) 35 (6.0)
Total protein (g/L) 70 (8.2) 70 (7.4)
Bilirubin (mmol/L) 36 (82) 37 (91)
Aspartate transaminase (mmol/L) 32 (30 57 (96)
Alkaline phosphatase (mmol/L) 169 (223) 169 (258)
Haemoglobin (mg/L) 12.3 (2.0) 12.3 (1.8)
Platelets (×109/L) 286 (117) 277 (84)
White cell count (×109/L) 7.8 (2.6) 7.8 (2.4)
International normalised ratio 1.0 (0.1) 1.0 (0.1)
Activated partial thromboplastin time (s) 30 (6.4) 30 (6.6)
TNM=tumour-nodes-metastases.
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not differ significantly between groups (P=0.83); can-
cer was the primary cause in 62% of epidural patients
and 57% of non-epidural patients (table 3).
DISCUSSION
Anaesthetics and cancer recurrence
Host defence is well established as the primary deter-
minant of progression of cancer, and function of nat-
ural killer cells is the single most important
component. The stress response to surgery, volatile
anaesthesia, and opioid administration all directly
impair natural killer cell function,3 6 and each effect is
ameliorated by spinal/epidural anaesthesia. In vitro,
animal, and some observational human data suggested
that epidural block would substantially reduce the risk
of recurrence of cancer.3 11-13Our results, though, fail to
support this hypothesis: recurrence-free survival and
mortality were nearly identical in both groups.
Bowel cancer is the third most common non-skin
cancer diagnosed in Australia and most other parts of
theworld.24 Thatmost of our patients had colon cancer
is thus unsurprising, especially as colectomies are
highly suitable for epidural anaesthesia. Tumour biol-
ogy varies considerably from organ to organ, and the
effects of regional block, if any, are likely to vary from
site to site. Although we had extremely limited power
for evaluating the independent effects of epidural block
on various types of cancer, we also found no evidence
that regional analgesia reduced recurrence of cancer or
mortality for any subgroup included in our analysis.
The major putative mechanisms by which regional
blockmight reduce the risk of recurrence of cancer are
decreasing the surgical stress response, reducing the
requirement for volatile anaesthesia, and obviating
the need for opioid administration. Nearly all our
patients were given thoracic epidural analgesia. The
thoracic approach blocks the sympathetic nervous sys-
tem and ameliorates immune suppression induced by
surgical stress much better than does lumbar epidural
anaesthesia25; it was thus ideal for our purpose. The
MASTER trial did not compare epidural anaesthesia
alonewith general anaesthesia alone. Instead, the com-
parison was between combined epidural and general
anaesthesia and general anaesthesia alone. The dose of
volatile anaesthetic was not recorded in the MASTER
trial but surely was reduced in the patients who
received epidural anaesthesia.26 Finally, postoperative
epidural analgesiawas effective in that themediandose
of opioid (in morphine sulphate equivalents) was 0 mg
in the epidural group compared with a median of
107 mg in the patients who had general anaesthesia
alone.
We identified other factors that were associated with
poorer cancer-free survival after surgery. These
included older age, female sex, tumour-nodes-
metastases status (results not shown), and intra-
operative red cell transfusion. These exploratory find-
ings are consistent with many previous studies and
support the internal validity of our dataset, as well as
providing confidence that we have not missed a true
independent effect of epidural block.
Comparison with other studies
Several small observational studies have evaluated the
effects of regional analgesia on recurrence of cancer;
some reported benefit,12 13 whereas others did not.14-16
However, no study randomly assigned patients to
regional analgesia; each was thus affected by selection
bias and confounding, which are inherent in observa-
tional analyses.27 Recurrence rates have only once
been reported in patients who were randomised to
Table 2 | Post-randomisation perioperative characteristics
Epidural (n=230) No epidural (n=216) P value
Intraoperative factors
Mean (SD) lowest temperature (°C) 35.5 (0.8) 35.6 (0.8) 0.16
Mean (SD) lowest blood pressure (mm Hg) 87 (15) 93 (17) <0.001
Mean (SD) highest heart rate (beats/min) 90 (17) 93 (20) 0.052
Median (IQR) crystalloid (mL) 2500 (2000-3725) 2400 (1500-3000) 0.11
Median (IQR) colloid (mL) 0 (0-1000) 0 (0-500) 0.005
No (%) red cell transfusion 45 (20) 27 (13) 0.043
No (%) blood product transfusion 46 (20) 29 (13) 0.064
Median (IQR) blood loss (mL) 300 (90-600) 300 (100-600) 0.39
Mean (SD) urine output (mL) 510 (456) 369 (341) 0.003
Postoperative pain scores—mean (SD)
Postoperative day 1 (am):
At rest 1.8 (2.4) 2.5 (2.3) 0.006
With coughing 4.0 (3.3) 5.5 (2.6) <0.001
Postoperative day 1 (pm):
At rest 1.6 (2.3) 2.1 (2.3) 0.042
With coughing 4.0 (3.0) 5.1 (2.6) <0.001
Postoperative day 2 (am):
At rest 1.4 (2.1) 1.5 (1.9) 0.59
With coughing 3.7 (2.8) 4.6 (2.6) 0.002
Postoperative day 2 (pm):
At rest 1.3 (1.9) 1.5 (2.1) 0.27
With coughing 3.3 (2.5) 4.3 (2.8) 0.001
Postoperative day 3 (am):
At rest 1.1 (1.8) 1.1 (1.7) 0.90
With coughing 3.1 (2.6) 3.8 (2.6) 0 028
Postoperative day 3 (pm):
At rest 1.0 (1.7) 1.1 (1.9) 0.62
With coughing 3.3 (2.6) 3.6 (2.7) 0.063
IQR=interquartile range.
Years
S
ur
vi
va
l
0 2 4 6 8 10 12
0
0.2
0.4
0.6
0.8
1.0
No epidural
Epidural
Fig 2 | Recurrence-free survival after cancer surgery by group
(log rank P=0.61)
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epidural analgesia or not.22However, only 145patients
with non-metastatic disease were included and the
results were equivocal, showing improved survival
up to 1.5 years with no difference thereafter.
Strengths and limitations of study
A strength of this study is that we compared its
9-15 years’ outcomes in a relatively large group of
patientswhowere randomly assigned to general anaes-
thesia combined with epidural anaesthesia and analge-
sia versus general anaesthesia and opioid analgesia.
Our sample size was limited by the size of the original
MASTER trial and the fraction of those patients who
had potentially curative surgery for cancer. Further-
more, follow-up data were not available for a small
fraction of the patients for various reasons. Our analy-
sis was thus restricted to 230 patients in the epidural
group and 215 patients in the non-epidural group. It
was well powered to detect a one third treatment effect
but lacked power to reliably detect smaller effects that
might still be of considerable clinical importance, par-
ticularly for individual types of cancer. Our study does
not provide information on the effects of regional
blockade on non-abdominal (for example, breast) can-
cers. Additional large trials are thus clearly warranted.
Several prospective randomised trials of regional
analgesia and recurrence of cancer have started in
recent years (NCT00684229, NCT00418457, and
NCT01179308). However, given the time needed for
enrolment of patients and prolonged observation for
recurrence, results will probably not be available for
five years or longer. Our results are likely to be the
only randomised data on this subject for years to
come. At the very least, our results suggest that in
vitro, animal, and observational human data about
regional block and recurrence of cancer should be
extrapolated to patients with considerable caution.
Although compelling short term reasons exist to use
epidural analgesia in many patients, reducing the
long term risk of recurrence of cancer may not be
among them.
Concerns have been raised about the expertise and
management of the epidural analgesia provided to
patients in the original MASTER trial.28 We thus pro-
vide some additional information in our methods sec-
tion. The failure rate of insertion was very low (4.6%),
and in any casewe could showeffective epidural block,
reduced pain scores, and a substantial reduction in
opioid administration in the postoperative period.
Conclusions and clinical decision making implications
In summary, we report the first long term follow-up of
recurrence of cancer in patients assigned to general
anaesthesia combined with epidural anaesthesia and
analgesia or to general anaesthesia with opioid analge-
sia. Cancer recurrence rates and mortality were nearly
identical in each group. The study had adequate power
to detect relative risk reductions of about a third but
Sex
  Male
  Female
Age (years)
  <60
  60-70
  >70
Type of surgery
  Oesophagogastric
  Hepatobiliary/pancreatic
  Bowel
  Renal
  Bladder-prostate
  Uterine-ovarian
  Other
All patients
1.10 (0.82 to 1.47)
0.83 (0.64 to 1.09)
1.00 (0.65 to 1.54)
0.91 (0.66 to 1.26)
0.96 (0.72 to 1.29)
1.02 (0.64 to 1.62)
0.80 (0.45 to 1.42)
0.91 (0.69 to 1.20)
1.31 (0.73 to 2.36)
1.67 (0.21 to 13.4)
0.81 (0.42 to 1.57)
0.95 (0.78 to 1.15)
53/138
39/92
13/31
33/75
46/124
9/24
7/34
55/128
6/11
4/8
11/20
0/5
92/230
0.1 10.5 432 5
Characteristics
Epidural
worse
Epidural
better
Risk ratio (95% CI)Risk ratio (95% CI)Epidural
39/113
53/102
16/38
36/74
40/103
12/33
8/28
51/108
7/19
1/3
13/20
0/5
92/215
Control
Fig 3 | Five year recurrence-free survival by subgroups. Tests for interaction were not
significant (all P>0.10)
Table 3 | Outcomes after surgery for cancer. Values are numbers (percentages) unless stated otherwise
Epidural
(n=230)
No epidural
(n=216)
Hazard ratio or risk ratio
(95% CI) P value
Primary end point
Median (95% CI) recurrence-free survival (years) 2.6 (1.0 to 4.7) 2.8 (1.7 to 3.8) 0.95 (0.76 to 1.17) 0.61
Secondary end points
Median (95% CI) time to recurrence (years) 1.1 (0.7 to 1.6) 1.4 (0.6 to 2.3) 0.63 (0.39 to 1.02) 0.056
Median (95% CI) survival (years) 3.3 (2.1 to 4.5) 3.7 (2.0 to 5.4) 0.95 (0.77 to 1.18) 0.66
At 5 years
Survival 96 (42) 94 (44) 0.96 (0.79 to 1.17) 0.70
Recurrence-free survival 92 (40) 92 (43) 0.95 (0.78 to 1.15) 0.58
Cause of death
Cancer 114/183 (62) 97/169 (57) –
0.83
Cardiovascular disease 25/183 (14) 27/169 (16) –
Sepsis 5/183 (3) 4/169 (2) –
Other 20/183 (11) 19/169 (11) –
Indeterminate or unknown 19/183 (10) 23/169 (14) –
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lacked power for smaller effects thatmight still be clini-
cally important. The decision to use epidural block in
combination with general anaesthesia for major sur-
gery for abdominal cancer should be based on other
considerations. For example, epidural analgesia
might be chosen to limit opioid related side effects or
avoided to reduce the risk of hypotension and addi-
tional need for intravenous fluids.
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We thank Barbara Chan, Data Linkage Unit, Australian Institute of Health
and Welfare, Canberra, Australia, for her assistance with some data
collection and Richard Parsons for facilitating ethics approval and data
management in Western Australia. Investigators and participating sites
are listed as a web extra on bmj.com.
Contributors: JRAR and KJ conceived the original MASTER trial, and DIS
conceived the follow-up cancer study. PSM, DIS, KJ, BS, and PP
contributed to study design. JH coordinated the data collection. PSM did
the statistical analyses. PSM and DIS wrote the first draft of the report.
PSM, PP, BS, JRAR, and DIS participated in interpreting the results and
editing the report. PSM is the guarantor.
Funding: The Australian National Health and Medical Research Council
funded the MASTER trial. The cancer follow-up study was funded by the
Australian and New Zealand College of Anaesthetists, the Alfred Hospital
Research Trust (Melbourne, Australia), and the Department of Outcomes
Research at the Cleveland Clinic (OH, USA). PSM is funded by an
Australian National Health and Medical Research Council practitioner
fellowship. The funders had no role in study design, data collection, data
analysis, data interpretation, or writing of the report.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: no support from any
organisation for the submitted work; no financial relationships with any
organisations that might have an interest in the submitted work in the
previous three years; no other relationships or activities that could appear
to have influenced the submitted work.
Ethical approval: For this follow-up study, additional ethics committee
approval was given by each of the original MASTER sites, the Australian
Institute of Health and Welfare (which is responsible for the National
Death Index), and cancer councils in each state of Australia.
Data sharing: Technical appendix, statistical code, and dataset are
available from the corresponding author at p.myles@alfred.org.au.
Participants’ consent was not obtained, but the presented data are
anonymised and risk of identification is low.
1 DenisMG, Lipart C, Leborgne J, LeHur PA, Galmiche JP, DenisM, et al.
Detection of disseminated tumor cells in peripheral blood of
colorectal cancer patients. Int J Cancer 1997;74:540-4.
2 Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against
postoperative immunosuppression: could they reduce recurrence
rates in oncological patients? Ann Surg Oncol 2003;10:972-92.
3 Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K,
Ben-Eliyahu S. Attenuation of the tumor-promoting effect of surgery
by spinal blockade in rats. Anesthesiology 2001;94:1066-73.
4 Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med
1998;49:407-24.
5 Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE,
McDonald PG, et al. The influence of bio-behavioural factors on
tumour biology: pathways and mechanisms. Nat Rev Cancer
2006;6:240-8.
6 Sacerdote P, BianchiM, Gaspani L,Manfredi B,Maucione A, TernoG,
et al. The effects of tramadol and morphine on immune responses
and pain after surgery in cancer patients. Anesth Analg
2000;90:1411-4.
7 Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, et al.
Morphine stimulates angiogenesis by activating proangiogenic and
survival-promoting signaling and promotes breast tumor growth.
Cancer Res 2002;62:4491-8.
8 Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress
and surgical interventions promote tumor development by
suppressing natural killer cell activity. Int J Cancer 1999;80:880-8.
9 O’Riain SC, Buggy DJ, KerinMJ,Watson RW,Moriarty DC. Inhibition of
the stress response to breast cancer surgery by regional anesthesia
and analgesia does not affect vascular endothelial growth factor and
prostaglandin E2. Anesth Analg 2005;100:244-9.
10 Chae BK, Lee HW, Sun K, Choi YH, Kim HM. The effect of combined
epidural and light general anesthesia on stress hormones in open
heart surgery patients. Surg Today 1998;28:727-31.
11 Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative
pain is a mediator of the tumor-promoting effects of surgery in rats.
Pain 2001;90:191-9.
12 Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can
anesthetic technique for primary breast cancer surgery affect
recurrence or metastasis? Anesthesiology 2006;4:660-4.
13 Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ.
Anesthetic technique for radical prostatectomy surgery affects
cancer recurrence: a retrospective analysis. Anesthesiology
2008;109:180-7.
14 Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, et al.
Association between epidural analgesia and cancer recurrence after
colorectal cancer surgery. Anesthesiology 2010;113:27-34.
15 Tsui BC, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J,
et al. Epidural anesthesia and cancer recurrence rates after radical
prostatectomy. Can J Anaesth 2010;57:107-12.
16 Ismail H, Ho KM, Narayan K, Kondalsamy-Chennakesavan S. Effect of
neuraxial anaesthesia on tumour progression in cervical cancer
patients treated with brachytherapy: a retrospective cohort study. Br
J Anaesth 2010;105:145-9.
17 Wuethrich PY, Hsu Schmitz SF, Kessler TM, Thalmann GN, Studer UE,
Stueber F, et al. Potential influence of the anesthetic technique used
during open radical prostatectomy on prostate cancer-related
outcome: a retrospective study. Anesthesiology 2010;113:570-6.
18 Rigg JRA, Jamrozik K,Myles PS, Silbert B, Peyton P, Parsons RW, et al.
Design of the multicenter Australian study of epidural anesthesia
and analgesia in major surgery: the MASTER Trial. Control Clin Trials
2000;21:244-56.
19 Rigg JRA, Jamrozik K,Myles PS, Silbert B, Peyton P, Parsons RW, et al.
Epidural anaesthesia and analgesia andoutcomeofmajor surgery: a
randomised trial. Lancet 2002;359:1276-82.
20 Peyton PJ, Myles PS, Silbert BS, Rigg JRA, Jamrozik K, Parsons RW,
et al. Perioperative epidural analgesia and outcome after major
abdominal surgery in high risk patients. Anesth Analg
2003;96:548-54.
21 American Joint Committee on Cancer. AJCC cancer staging manual.
6th ed. Springer, 2002.
22 Christopherson R, James KE, Tableman M, Marshall P, Johnson FE.
Long-term survival after colon cancer surgery: a variation associated
with choice of anesthesia. Anesth Analg 2008;107:325-32.
23 Breslow NE, Day NE. Statistical methods in cancer research. Volume
I: the analysis of case-control studies. IARC Sci Publ 1980;32:5-338.
24 Australian Institute of Health andWelfare. Cancer in Australia: an
overview 2010. AIHW, 2010 (available at www.aihw.gov.au/
publications/can/56/12138.pdf). (Cancer series no 60.)
25 Ahlers O, Nachtigall I, Lenze J, Goldmann A, Schulte E, Höhne C, et al.
Intraoperative thoracic epidural anaesthesia attenuates stress-
induced immunosuppression in patients undergoing major
abdominal surgery. Br J Anaesth 2008;101:781-7.
26 Hodgson PS, Liu SS. Epidural lidocaine decreases sevoflurane
requirement for adequate depth of anesthesia as measured by the
bispectral index monitor. Anesthesiology 2001;94:799-803.
27 Collins R, MacMahon S. Reliable assessment of the effects of
treatmentonmortality andmajormorbidity, II: observational studies.
Lancet 2001;357:455-62.
28 De Leon-Casasola OA. When it comes to outcome, we need to define
what a perioperative epidural technique is. Anesth Analg
2003;96:315-8.
Accepted: 31 January 2011
WHAT IS ALREADY KNOWN ON THIS TOPIC
Recent observational studies have found a strong association between use of local
anaesthetic (regional) block for cancer surgery and reductions in late recurrence of cancer
Whether selection of patients, other perioperative factors, or detection bias can explain these
findings is unclear
WHAT THIS STUDY ADDS
This randomised trial could not identify any reduction in recurrence of cancer or survival when
epidural block was used for surgery for abdominal cancer
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